Agnieszka Mizia-Malarz
Dados Biográficos
| ID | 8267665 |
|---|---|
| NOME | Agnieszka Mizia-Malarz |
| PRENOMES | Agnieszka |
| SOBRENOME | Mizia-Malarz |
| ASSINATURA | MIZIA-MALARZ A |
| AFILIAÇÕES | Medical University of Silesia |
| VERIFICADO | Não |
| TOTAL DE OBRAS | 2 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 2 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2022 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2026 |
| ÍNDICE H | 0 |
The Outcomes of Myeloid Sarcoma in 64 Pediatric Patients and the Impact of Allogeneic Hematopoietic Stem Cell Transplantation on Treatment Results
Background: Myeloid sarcoma (MS) is a malignant extramedullary tumor that occurs in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML). The standard first-line treatment for MS is intensive chemotherapy according to the AML protocol, regardless of bone marrow involvement. The role of allogeneic hematopoietic stem cell transplantation (alloHSCT) in the treatment of pediatric patients with …
Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience
The prognosis in children and adolescents with relapsed ALL, despite intensive therapy, including hematopoietic stem cell transplantation, is still challenging. This study aims to analyze the incidence of relapsed ALL and survival rates in correlation to the risk factors. Materials and methods: 125 pediatric patients with ALL diagnosed in our department between 2000-2018; age 1−18 years old (median 6.4); female 53.6% vs. male 46.4%. Results: 19 p…
Sem obras proeminentes nesta página.
Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience
The prognosis in children and adolescents with relapsed ALL, despite intensive therapy, including hematopoietic stem cell transplantation, is still challenging. This study aims to analyze the incidence of relapsed ALL and survival rates in correlation to the risk factors. Materials and methods: 125 pediatric patients with ALL diagnosed in our department between 2000-2018; age 1−18 years old (median 6.4); female 53.6% vs. male 46.4%. Results: 19 p…
The Outcomes of Myeloid Sarcoma in 64 Pediatric Patients and the Impact of Allogeneic Hematopoietic Stem Cell Transplantation on Treatment Results
Background: Myeloid sarcoma (MS) is a malignant extramedullary tumor that occurs in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML). The standard first-line treatment for MS is intensive chemotherapy according to the AML protocol, regardless of bone marrow involvement. The role of allogeneic hematopoietic stem cell transplantation (alloHSCT) in the treatment of pediatric patients with …
Chemotherapy (2 obras) · Hematopoietic Stem Cell Transplantation (2 obras) · Leukemia (2 obras) · Transplantation (2 obras) · Acute Lymphoblastic Leukemia research (1 obras) · Acute Myeloid Leukemia Research (1 obras) · Bone marrow (1 obras) · Childhood Cancer Survivors' Quality of Life (1 obras) · Chronic Myeloid Leukemia Treatments (1 obras) · Cohort (1 obras)